本期看点：1. GSPT1靶向分子胶降解剂用于治疗转移性去势抵抗性前列腺癌（mCRPC）的早期临床试验结果积极，携带雄激素受体（AR）突变患者的靶病灶均观察到缩小，疾病控制率达100%。2. PRO-XTEN双掩蔽CD3 ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Real-world PRECISION data in 500 taxane-naïve, PSMA-positive mCRPC patients showed median PFS 13.5 months (95% CI, 11.7–14.7), aligning with PSMAfore efficacy expectations. Earlier sequencing mattered ...

Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of ...

Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux’s ...

Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer that has spread to other parts of the body. It no longer responds to treatments that block testosterone, a ...